Pharming Group NV

Price Chart

Risk-Adjusted Performance

Also Listed On

Pharming Group NV (PHAR) Price Performance

Pharming Group NV (PHAR) trades on United States in USD. The company is classified in the Healthcare sector under the Biotechnology industry. The stock currently trades at $17.34, up 0.06% from the previous close.

Over the past year, PHAR has traded between a low of $8.27 and a high of $21.18. The stock has gained 106.6% over this period. It is currently 18.1% below its 52-week high.

Pharming Group NV has a market capitalization of $1.01B, with a price-to-earnings ratio of 415.32.

About Pharming Group NV

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company's lead product is RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K" inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. It has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.